Karyopharm therapeutics inc. (KPTI)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Sep'12
Revenues:
Total revenues

18,138

18,096

13,149

9,493

155

206

239

19,891

10,000

1,534

0

3

68

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Contract and grant revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

-

48

59

-

-

75

150

-

16

21

21

171

21

0

133

233

34

Operating expenses:
Cost of sales

819

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cost of sales

-

-

1,013

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Research and development

33,997

31,579

26,270

26,517

37,974

38,890

36,427

44,734

41,321

34,833

25,237

23,120

24,083

20,671

19,893

24,579

21,795

24,064

25,923

27,006

20,751

20,038

15,951

13,159

10,979

9,689

7,738

6,060

4,965

2,997

Selling, general and administrative

30,678

-

25,267

-

27,103

-

12,966

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

General and administrative

-

-

-

24,662

-

-

-

9,489

7,621

-

5,818

6,635

6,264

6,541

5,897

5,956

5,554

5,264

4,762

6,157

5,399

5,920

3,814

3,310

2,904

2,480

1,583

943

879

672

Total operating expenses

65,494

61,362

52,550

51,179

65,077

57,661

49,393

54,223

48,942

40,986

31,055

29,755

30,347

27,212

25,790

30,535

27,349

29,328

30,685

33,163

26,150

25,958

19,765

16,469

13,883

12,169

9,321

7,003

5,844

3,669

Loss from operations

-47,356

-43,266

-39,401

-41,686

-64,922

-57,455

-49,154

-34,332

-38,942

-39,452

-31,055

-29,752

-30,279

-27,165

-25,742

-30,476

-27,349

-29,303

-30,610

-33,013

-26,150

-25,942

-19,744

-16,448

-13,712

-12,148

-9,321

-6,870

-5,611

-3,635

Other income (expense):
Interest income

975

1,102

1,137

1,412

1,771

1,768

1,098

653

509

432

454

412

400

358

311

329

286

250

239

267

141

42

20

17

18

-

-

-

-

-

Interest expense

6,509

6,467

3,093

3,089

2,998

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other income (expense), net

25

-14

10

-44

-2

-13

-13

7

-14

-11

-26

-29

-15

11

6

-11

4

7

-2

51

-58

-

-

17

18

-

-

-

-

-

Total other expense, net

-5,509

-5,379

-1,946

-1,721

-1,229

-738

1,085

660

495

421

428

383

385

369

317

318

290

257

237

318

83

-

20

-

-

-

-

1

-

-

Loss before income taxes

-52,865

-48,645

-41,347

-43,407

-66,151

-58,193

-48,069

-33,672

-38,447

-39,031

-30,627

-29,369

-29,894

-26,796

-25,425

-30,158

-27,059

-

-

-

-

-

-

-

-

-

-

-

-

-

Income tax provision

66

2

20

8

10

17

14

-17

12

9

13

18

23

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss

-52,931

-48,647

-41,367

-43,415

-66,161

-58,210

-48,083

-33,655

-38,459

-39,040

-30,640

-29,387

-29,917

-26,935

-25,425

-30,158

-27,059

-29,046

-30,373

-32,695

-26,067

-25,928

-19,724

-16,431

-13,694

-12,146

-9,321

-6,869

-5,611

-3,635

Net loss per share—basic and diluted

-0.78

-0.75

-0.67

-0.71

-1.09

-0.97

-0.79

-0.60

-0.78

-0.81

-0.65

-0.64

-0.71

-0.64

-0.69

-0.84

-0.75

-0.81

-0.85

-0.92

-0.74

-0.81

-0.61

-0.55

-0.46

3.45

-3.66

-2.86

-2.52

1,846,859.00

Weighted-average number of common shares outstanding used in net loss per share—basic and diluted

67

124,738

62,092

60,929

60

60,920

60,586

56,089

49,602

48,731

47,141

45,831

41,894

41,437

36,819

35,956

35,878

35,755

35,708

35,697

35,317

32,717

32,558

29,659

29,606

17,096

2,544

2,404

2,225

-0

Comprehensive loss

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-9,321

-6,869

-5,611

-

Product revenue
Total revenues

16,100

-

12,821

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

License and other revenue
Total revenues

2,077

-

328

-

155

-

239

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-